[Monoclonal antibodies and their targets in the treatment of multiple sclerosis].
St. Josef-Hospital, Ruhr-Universität Bochum.
A
A
Chan
D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018951:Antigens, CD20 / Q000276:immunology; D000077561:Daclizumab; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007962:Leukocytes / Q000276:immunology / Q000502:physiology; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D014409:Tumor Necrosis Factor-alpha; D000074323:Alemtuzumab; D000077561:Daclizumab